Cambridge, UK, 17 July 2019: Mogrify Ltd (Mogrify), a company aiming to transform the future development of cell therapies, today announced it will host a careers day at the Bio-Innovation Centre, 25 Cambridge Science Park on Friday, 16th August 2019 from 4–6pm. The event will showcase careers in the biotech industry, specifically in cell therapy and regenerative medicine, and offer attendees the opportunity to visit the Company’s research laboratories, and meet with the founders and current employees.
Alloy Therapeutics UK Ltd are a start-up company from the USA and required lab and office space for 15 scientist with two Cat II cell biology labs, a Cat II molecular biology lab for 10, a meeting room and write up space.
Jul. 16, 2019--
Research Triangle Park, NC, USA and Cambridge, UK, and Dubai, UAE , July 16, 2019 -- Inivata, a leader in liquid biopsy, has signed a distribution agreement with IPS Genomix, part of the IPS Group, to provide cancer patients and partners in the Middle East and Africa with access to its InVisionFirst®-Lung and InVisionSeq™ liquid biopsy tests.
The move will facilitate planned future growth for the successful natural products discovery and development provider
Cambridge, UK, 16th July 2019: Chesterford Research Park is delighted to confirm that Isomerase will take up occupancy within Suite 4 of the Newnham Building upon its completion in mid 2020.
Despite improving survival rates, cancer is the leading cause of death in children and young people. There is a growing need for technology to support children and young people with cancer, as well as to support health care professionals to provide optimal care.
NIHR Children and Young People MedTech Co-operative (NIHR CYP MedTech) collaborated with the Academic Health Science Network North East and North Cumbria, NIHR Clinical Research Network North East and North Cumbria, MedConnect North, and Lab4Living to deliver an innovation workshop at The Biosphere, Newcastle Helix.
Cambridge, UK, 15 July 2019: PhoreMost Limited, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has appointed Dr Lorenz Mayr to its Board as Non-Executive Director. Dr Mayr’s experience in drug discovery and development, and specifically his expertise in functional genetic screening in target identification, will help drive the expansion of PhoreMost’s next-generation SITESEEKER® target discovery platform and guide the development of the Company’s drug discovery programme.
Planning to attend the BioWednesday Summer Social on 14 August 2019? Do you fancy winning one of our wise owls? By registering and attending the event, you are automatically entered into the competiton to win one of the below owls!
• Career that spans biotech and pharma including at Astex Pharmaceuticals and GSK
• Has led discovery of over 10 drugs taken into clinical development, including the two recent drugs from the Astex stable that have received marketing approval
• Will grow in-house drug development team to harness power of AI and take rare disease treatments from prediction through to the clinical stage